Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis

Medical Oncology

Volumn 31, Issue 4, 2014, Pages

  Chen, Kangwu ^a   Mo, Jianqiang ^a   Zhou, Ming ^a   Wang, Genlin ^a   Wu, Guizhong ^a   Chen, Hao ^a   Zhang, Kai ^a   Yang, Huilin ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Chordoma; mTOR; Prognosis; PTEN; Sacrum

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; MTOR PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CHORDOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PELVIS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACRAL CHORDOMA; SACRUM; TUMOR INVASION; ADOLESCENT; AGED; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SPINAL CORD TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHORDOMA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SACRUM; SPINAL NEOPLASMS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84893719077     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0886-7     Document Type: Article

References (21)

1. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr Opin Oncol. 2007;19:367-70.
2. Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH. Operative management of sacral chordoma. J Bone Joint Surg Am. 2005;87:2211-6.
3. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007;12:1344-50.
4. Pal SK, Figlin RA, Reckamp KL. The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 2008;9:340-5.
5. Contreras AG, Dormond O, Edelbauer M, Calzadilla K, Hoerning A, Pal S, Briscoe DM. mTOR-understanding the clinical effects. Transplant Proc. 2008;40:S9-12.
6. McBride SM, Perez DA, Polley MY, et al. Activation of PI3 K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010;97:33-40.
7. Han W, Ming M, He TC, He YY. Immunosuppressive cyclospor in Aactivates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem. 2010;285:11369-77.
8. Chen KW, Yang HL, Lu J, Liu JY, Chen XQ. Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients. Spinal Cord. 2010;48:166-71.
9. Chen KW, Yang HL, Lu J, et al. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J Neurooncol. 2011;101:357-63.
10. Chen C, Yang HL, Chen KW, et al. High expression of survivin in sacral chordoma. Med Oncol. 2013;30:529.
11. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschlager M. The mTOR pathway and its role in human genetic diseases. Mutat Res. 2008;659:284-92.
12. Scheper MA, Chaisuparat R, Nikitakis NG, Sauk JJ. Expression and alterations of the PTEN/AKT/mTOR pathway in ameloblastomas. Oral Dis. 2008;14:561-8.
13. Presneau N, Shalaby A, Idowu B, et al. Potential therapeutic targets for chordoma: PI3 K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer. 2009;100:1406-14.
14. Schwab J, Antonescu C, Boland P, et al. Combination of PI3 K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res. 2009;29:1867-71.
15. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926-45.
16. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-7.
17. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;57:4736-8.
18. Bakarakos P, Theohari I, Nomikos A, Mylona E, et al. Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breastcarcinomas. Histopathology. 2010;56:876-82.
19. Cheng ZY, Guo XL, Yang XY, et al. PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. J Exp Clin Cancer Res. 2008;27:87.
20. Han S, Polizzano C, Nielsen GP, Hornicek FJ, Rosenberg AE, Ramesh V. Aberrant hyperactivation of akt and mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res. 2009;15:1940-6.
21. Wang L, Yue W, Zhang L, Zhao X, Wang Y, Xu S. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry. Surg Today. 2012;42:419-25.